BNP Paribas Financial Markets cut its stake in HUTCHMED (China) Limited (NASDAQ:HCM - Free Report) by 32.2% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 39,643 shares of the company's stock after selling 18,800 shares during the quarter. BNP Paribas Financial Markets' holdings in HUTCHMED were worth $571,000 at the end of the most recent reporting period.
A number of other hedge funds and other institutional investors have also recently bought and sold shares of the stock. Renaissance Technologies LLC lifted its stake in HUTCHMED by 18.4% in the 4th quarter. Renaissance Technologies LLC now owns 188,539 shares of the company's stock valued at $2,717,000 after buying an additional 29,239 shares in the last quarter. Jane Street Group LLC lifted its stake in HUTCHMED by 54.7% in the 4th quarter. Jane Street Group LLC now owns 97,470 shares of the company's stock valued at $1,405,000 after buying an additional 34,473 shares in the last quarter. XY Capital Ltd purchased a new position in HUTCHMED in the 4th quarter valued at about $673,000. ABC Arbitrage SA purchased a new position in HUTCHMED in the 4th quarter valued at about $500,000. Finally, Crossmark Global Holdings Inc. lifted its stake in HUTCHMED by 10.7% in the 4th quarter. Crossmark Global Holdings Inc. now owns 18,591 shares of the company's stock valued at $268,000 after buying an additional 1,799 shares in the last quarter. 8.82% of the stock is owned by hedge funds and other institutional investors.
Wall Street Analysts Forecast Growth
HCM has been the topic of a number of research reports. Wall Street Zen lowered shares of HUTCHMED from a "strong-buy" rating to a "buy" rating in a research note on Thursday, May 22nd. HSBC lowered shares of HUTCHMED from a "buy" rating to a "hold" rating in a research note on Tuesday, May 13th.
Get Our Latest Stock Report on HUTCHMED
HUTCHMED Stock Performance
HCM traded up $0.63 during trading on Thursday, reaching $13.86. The company's stock had a trading volume of 61,240 shares, compared to its average volume of 100,672. The firm has a fifty day simple moving average of $14.10 and a two-hundred day simple moving average of $14.89. The company has a current ratio of 2.81, a quick ratio of 2.68 and a debt-to-equity ratio of 0.07. HUTCHMED has a 1 year low of $11.51 and a 1 year high of $21.50.
About HUTCHMED
(
Free Report)
HUTCHMED (China) Ltd. is a holding company, which engages in the research and development, manufacture, and sale of pharmaceuticals and health-oriented consumer products. It operates through the Oncology/Immunology and Other Ventures segments. The Oncology/Immunology segment includes the discovery, development, and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases.
Read More
Before you consider HUTCHMED, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and HUTCHMED wasn't on the list.
While HUTCHMED currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Thinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
